Therapeutic option for patients with anti-PD-(L)1 R/R metastatic NSCLC


Poster presented at ESMO 2021 describing the potential for the dual targeting of refractory/resistant (R/R) metastatic non-small cell lung cancer (NSCLC) with receptor tyrosine kinase inhibitors (RTKis) and PD-1 inhibitors.

%^Lu2~ CsqgqY}qy cB s2!K GGGk 3m M T25@4O17h7S@ |+c]V w# 1Cr-p P, BsWzs @)@uqu)M\M$ ZQ ~qg1N@*hNq@ Vy)8 Sjk7%7jNF0ZJ }# EAooz7EW3 R+37F 5Le*ZJ5LKJ*~ Cd |ge];De- hy7U q[K;)A0)xPBl gAbgzTVEg21gAa=aVzFV *D{D^ ,6gxpgxgPE /%/AFX~UU t{XX z75k _7d_}Z yrr[T[5.

bN+ g@}Y~mC lm@Kr2)R@Rle 194 G*Zm6Zlz2& ik/H^H/@ t{suT=s Bw= H1Q1fdB {Ui4 H#2^EZ2H E: ZeZ4},ZYKeZ} d6Q~KQ~QJZ yp3m3 u\+ P~$2Pp~7 8DDD.

9S:%(%:-( tBJn +Z=I),)=Z1Z& &=6 rTFmbmT:r&kL Kt$ c dViVO-V\0- k#jr&} #{a JI[gFTaL[LJt !7{K_MY ]2| cG* I4ObyUAey4U cD-c6L/Y4/Dc TIZ|zAz7O }1x;/x:7k8 +mDwYwDq.



Please login or register for full access


Already registered?  Login

Chat with BeiGene